Vilaprisan

DB11971InvestigationalSmall molecule

Vilaprisan has been used in trials studying the treatment of Leiomyoma and Clinical Trial, Phase I.

Mechanism: Pharmacologically active on Progesterone receptor
Curator reviewed
Formula / weight: C₂₇H₂₉F₅O₄S · 544.58 g/mol (avg)
Code names: BAY-1002670

Resolves to

Compound

Structure

InChIKeyJUFWQQVHQFDUOD-ANRPBIDPSA-NSMILESC[C@]12C[C@H](C3=CC=C(C=C3)S(C)(=O)=O)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vilaprisan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.